Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCHANTMENT HIV: Sacubitril/Valsartan for Subclinical Heart Failure in HIV
NCT04153136Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Massachusetts General Hospital. Started Sep 2020; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04153136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153136.